Erratum: Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease (Cell Metabolism (2017) 25(5) (1054–1062.e5), (S1550413117302061), (10.1016/j.cmet.2017.04.001));Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease

Cell Metabolism

Volumn 25, Issue 5, 2017, Pages 1054-1062.e5

  Loomba, Rohit ^a,b   Seguritan, Victor ^c   Li, Weizhong ^c,d   Long, Tao ^c   Klitgord, Niels ^c   Bhatt, Archana ^a   Dulai, Parambir Singh ^a   Caussy, Cyrielle ^a   Bettencourt, Richele ^a   Highlander, Sarah K ^d   Jones, Marcus B ^c   Sirlin, Claude B ^e   Schnabl, Bernd ^a   Brinkac, Lauren ^d   Schork, Nicholas ^d   Chen, Chi Hua ^e   Brenner, David A ^a   Biggs, William ^c   Yooseph, Shibu ^c,d   Venter, J Craig ^c,d   Nelson, Karen E ^c,d   more..

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Human Longevity Inc   (United States)

^d J CRAIG VENTER INSTITUTE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

biomarker; cirrhosis; fatty liver; fibrosis; hepatic steatosis; hepatitis; liver disease; microbiome; NASH; non invasive

Indexed keywords

DNA;

ADULT; ARTICLE; BACTERIUM; CLASSIFIER; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; FECES ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTESTINE FLORA; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; METAGENOMICS; MICROBIAL METABOLISM; MIDDLE AGED; MODEL; NON INVASIVE MEASUREMENT; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOM FOREST; SPECIES; STAGING; TAXONOMY; AGED; FECES; GENETICS; ISOLATION AND PURIFICATION; LIVER CIRRHOSIS; MICROBIOLOGY; PROCEDURES; PROGNOSIS;

ADULT; AGED; BACTERIA; FECES; FEMALE; GASTROINTESTINAL MICROBIOME; HUMANS; LIVER CIRRHOSIS; MALE; METAGENOMICS; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 85018954191     PISSN: 15504131     EISSN: 19327420     Source Type: Journal    
DOI: 10.1016/j.cmet.2019.08.002     Document Type: Erratum

References (46)

1. Adams, L.A., Lymp, J.F., St Sauver, J., Sanderson, S.O., Lindor, K.D., Feldstein, A., Angulo, P., The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129 (2005), 113–121.
2. Affò, S., Morales-Ibanez, O., Rodrigo-Torres, D., Altamirano, J., Blaya, D., Dapito, D.H., Millán, C., Coll, M., Caviglia, J.M., Arroyo, V., et al. CCL20 mediates lipopolysaccharide induced liver injury and is a potential driver of inflammation and fibrosis in alcoholic hepatitis. Gut 63 (2014), 1782–1792.
3. Anand, G., Zarrinpar, A., Loomba, R., Targeting dysbiosis for the treatment of liver disease. Semin. Liver Dis. 36 (2016), 37–47.
4. Angulo, P., Kleiner, D.E., Dam-Larsen, S., Adams, L.A., Bjornsson, E.S., Charatcharoenwitthaya, P., Mills, P.R., Keach, J.C., Lafferty, H.D., Stahler, A., et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology, 149, 2015 389–97.e10.
5. Bai, L., Kong, M., Zheng, Q., Zhang, X., Liu, X., Zu, K., Chen, Y., Zheng, S., Li, J., Ren, F., et al. Inhibition of the translocation and extracellular release of high-mobility group box 1 alleviates liver damage in fibrotic mice in response to D-galactosamine/lipopolysaccharide challenge. Mol. Med. Rep. 13 (2016), 3835–3841.
6. Bajaj, J.S., Heuman, D.M., Hylemon, P.B., Sanyal, A.J., White, M.B., Monteith, P., Noble, N.A., Unser, A.B., Daita, K., Fisher, A.R., et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J. Hepatol. 60 (2014), 940–947.
7. Betrapally, N.S., Gillevet, P.M., Bajaj, J.S., Changes in the intestinal microbiome and alcoholic and nonalcoholic liver diseases: causes or effects?. Gastroenterology 150 (2016), 1745–1755.e3.
8. Bhala, N., Angulo, P., van der Poorten, D., Lee, E., Hui, J.M., Saracco, G., Adams, L.A., Charatcharoenwitthaya, P., Topping, J.H., Bugianesi, E., et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 54 (2011), 1208–1216.
9. Boursier, J., Mueller, O., Barret, M., Machado, M., Fizanne, L., Araujo-Perez, F., Guy, C.D., Seed, P.C., Rawls, J.F., David, L.A., et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology 63 (2016), 764–775.
10. Breiman, L., Random forests. Mach. Learn. 45 (2001), 5–32.
11. Chen, Y.M., Liu, Y., Zhou, R.F., Chen, X.L., Wang, C., Tan, X.Y., Wang, L.J., Zheng, R.D., Zhang, H.W., Ling, W.H., Zhu, H.L., Associations of gut-flora-dependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults. Sci. Rep., 6, 2016, 19076.
12. Cui, J., Chen, C.H., Lo, M.T., Schork, N., Bettencourt, R., Gonzalez, M.P., Bhatt, A., Hooker, J., Shaffer, K., Nelson, K.E., et al., For The Genetics Of Nafld In Twins Consortium. Shared genetic effects between hepatic steatosis and fibrosis: A prospective twin study. Hepatology 64 (2016), 1547–1558.
13. De Minicis, S., Rychlicki, C., Agostinelli, L., Saccomanno, S., Candelaresi, C., Trozzi, L., Mingarelli, E., Facinelli, B., Magi, G., Palmieri, C., et al. Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice. Hepatology 59 (2014), 1738–1749.
14. Decaris, M.L., Li, K.W., Emson, C.L., Gatmaitan, M., Liu, S., Wang, Y., Nyangau, E., Colangelo, M., Angel, T.E., Beysen, C., et al. Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood. Hepatology 65 (2017), 78–88.
15. Dulai, P.S., Sirlin, C.B., Loomba, R., MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice. J. Hepatol. 65 (2016), 1006–1016.
16. Dulai, P.S., Singh, S., Patel, J., Soni, M., Prokop, L.J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology, 2017, 10.1002/hep.29085 Published online January 28, 2017.
17. Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., Hultcrantz, R., Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61 (2015), 1547–1554.
18. Forslund, K., Hildebrand, F., Nielsen, T., Falony, G., Le Chatelier, E., Sunagawa, S., Prifti, E., Vieira-Silva, S., Gudmundsdottir, V., Krogh Pedersen, H., et al., MetaHIT consortium. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 528 (2015), 262–266.
19. Gill, S.R., Pop, M., Deboy, R.T., Eckburg, P.B., Turnbaugh, P.J., Samuel, B.S., Gordon, J.I., Relman, D.A., Fraser-Liggett, C.M., Nelson, K.E., Metagenomic analysis of the human distal gut microbiome. Science 312 (2006), 1355–1359.
20. Guo, L., Milburn, M.V., Ryals, J.A., Lonergan, S.C., Mitchell, M.W., Wulff, J.E., Alexander, D.C., Evans, A.M., Bridgewater, B., Miller, L., et al. Plasma metabolomic profiles enhance precision medicine for volunteers of normal health. Proc. Natl. Acad. Sci. USA 112 (2015), E4901–E4910.
21. Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W.Z., Strowig, T., Thaiss, C.A., Kau, A.L., Eisenbarth, S.C., Jurczak, M.J., et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482 (2012), 179–185.
22. Jones, M.B., Highlander, S.K., Anderson, E.L., Li, W., Dayrit, M., Klitgord, N., Fabani, M.M., Seguritan, V., Green, J., Pride, D.T., et al. Library preparation methodology can influence genomic and functional predictions in human microbiome research. Proc. Natl. Acad. Sci. USA 112 (2015), 14024–14029.
23. Kakiyama, G., Pandak, W.M., Gillevet, P.M., Hylemon, P.B., Heuman, D.M., Daita, K., Takei, H., Muto, A., Nittono, H., Ridlon, J.M., et al. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J. Hepatol. 58 (2013), 949–955.
24. Karp, P.D., Paley, S., Romero, P., The Pathway Tools software. Bioinformatics 18:Suppl 1 (2002), S225–S232.
25. Kleiner, D.E., Brunt, E.M., Van Natta, M., Behling, C., Contos, M.J., Cummings, O.W., Ferrell, L.D., Liu, Y.C., Torbenson, M.S., Unalp-Arida, A., et al., Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005), 1313–1321.
26. Lelouvier, B., Servant, F., Païssé, S., Brunet, A.C., Benyahya, S., Serino, M., Valle, C., Ortiz, M.R., Puig, J., Courtney, M., et al. Changes in blood microbiota profiles associated with liver fibrosis in obese patients: A pilot analysis. Hepatology 64 (2016), 2015–2027.
27. Liaw, A., Classification and regression by randomForest. R news 2 (2002), 18–22.
28. Liu, H., Pathak, P., Boehme, S., Chiang, J.Y., Cholesterol 7α-hydroxylase protects the liver from inflammation and fibrosis by maintaining cholesterol homeostasis. J. Lipid Res. 57 (2016), 1831–1844.
29. Loomba, R., Sanyal, A.J., The global NAFLD epidemic. Nat. Rev. Gastroenterol. Hepatol. 10 (2013), 686–690.
30. Loomba, R., Schork, N., Chen, C.H., Bettencourt, R., Bhatt, A., Ang, B., Nguyen, P., Hernandez, C., Richards, L., Salotti, J., et al., Genetics of NAFLD in Twins Consortium. Heritability of hepatic fibrosis and steatosis based on a prospective twin study. Gastroenterology 149 (2015), 1784–1793.
31. Mardinoglu, A., Boren, J., Smith, U., Confounding effects of metformin on the human gut microbiome in type 2 diabetes. Cell Metab. 23 (2016), 10–12.
32. Matteoni, C.A., Younossi, Z.M., Gramlich, T., Boparai, N., Liu, Y.C., McCullough, A.J., Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116 (1999), 1413–1419.
33. Moss, C.W., Lambert, M.A., Goldsmith, D.J., Production of hydrocinnamic acid by clostridia. Appl. Microbiol. 19 (1970), 375–378.
34. Nelson, K.E., Weinstock, G.M., Highlander, S.K., Worley, K.C., Creasy, H.H., Wortman, J.R., Rusch, D.B., Mitreva, M., Sodergren, E., Chinwalla, A.T., et al., Human Microbiome Jumpstart Reference Strains Consortium. A catalog of reference genomes from the human microbiome. Science 328 (2010), 994–999.
35. Noguchi, H., Park, J., Takagi, T., MetaGene: prokaryotic gene finding from environmental genome shotgun sequences. Nucleic Acids Res. 34 (2006), 5623–5630.
36. Qin, N., Yang, F., Li, A., Prifti, E., Chen, Y., Shao, L., Guo, J., Le Chatelier, E., Yao, J., Wu, L., et al. Alterations of the human gut microbiome in liver cirrhosis. Nature 513 (2014), 59–64.
37. Rinella, M.E., Nonalcoholic fatty liver disease: a systematic review. JAMA 313 (2015), 2263–2273.
38. Seki, E., De Minicis, S., Osterreicher, C.H., Kluwe, J., Osawa, Y., Brenner, D.A., Schwabe, R.F., TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat. Med. 13 (2007), 1324–1332.
39. Singh, S., Allen, A.M., Wang, Z., Prokop, L.J., Murad, M.H., Loomba, R., Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin. Gastroenterol. Hepatol., 13, 2015 643–54.e1, 9, quiz e39–e40.
40. Turnbaugh, P.J., Hamady, M., Yatsunenko, T., Cantarel, B.L., Duncan, A., Ley, R.E., Sogin, M.L., Jones, W.J., Roe, B.A., Affourtit, J.P., et al. A core gut microbiome in obese and lean twins. Nature 457 (2009), 480–484.
41. Vernon, G., Baranova, A., Younossi, Z.M., Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment. Pharmacol. Ther. 34 (2011), 274–285.
42. Wikoff, W.R., Anfora, A.T., Liu, J., Schultz, P.G., Lesley, S.A., Peters, E.C., Siuzdak, G., Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc. Natl. Acad. Sci. USA 106 (2009), 3698–3703.
43. Wong, V.W., Wong, G.L., Choi, P.C., Chan, A.W., Li, M.K., Chan, H.Y., Chim, A.M., Yu, J., Sung, J.J., Chan, H.L., Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 59 (2010), 969–974.
44. Younossi, Z.M., Koenig, A.B., Abdelatif, D., Fazel, Y., Henry, L., Wymer, M., Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64 (2016), 73–84.
45. Zarrinpar, A., Gupta, S., Maurya, M.R., Subramaniam, S., Loomba, R., Serum microRNAs explain discordance of non-alcoholic fatty liver disease in monozygotic and dizygotic twins: a prospective study. Gut 65 (2016), 1546–1554.
46. Zhu, L., Baker, S.S., Gill, C., Liu, W., Alkhouri, R., Baker, R.D., Gill, S.R., Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 57 (2013), 601–609.